Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co Buyback Yield % Chart
TSE:4594 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a Buyback Yield % of -41.93 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BrightPath Biotherapeutics Co and its competitors. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #602 out of 740 companies in the Biotechnology industry, placing it in the top 81.4%.
Is BrightPath Biotherapeutics Co's Buyback Yield % too high?
BrightPath Biotherapeutics Co's current Buyback Yield % is -41.93. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #602 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #602 out of 740 companies for Buyback Yield %. This places BrightPath Biotherapeutics Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current Buyback Yield % is -41.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.62, compared to a current price of 円47.00 — trading 917.3% above its estimated fair value. The current Buyback Yield % is -41.93. BrightPath Biotherapeutics Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Buyback Yield % is -41.93 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued.
The current stock price of 円47.00 is trading 917.3% above its estimated GF Value™ of 円4.62.
GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.
Key valuation signals for TSE:4594:
Buyback Yield %: -41.93
GF Value™: 円4.62 vs. price of 円47.00 (917.3% above fair value)
No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrightPath Biotherapeutics Co Business Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score
Get the complete analysis for TSE:4594
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
